menu
    • menu
    [{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tofacitinib Etocomil","moa":"JAK","graph1":"Dermatology","graph2":"Phase III","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Minghui Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Minghui Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tofacitinib Etocomil","moa":"JAK","graph1":"Dermatology","graph2":"Phase III","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Minghui Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Minghui Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tofacitinib Etocomil","moa":"JAK","graph1":"Dermatology","graph2":"Phase III","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Minghui Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Minghui Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"MHB018A","moa":"IGF-1\/IGF-2 receptor","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Minghui Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Minghui Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"MHB018A","moa":"IGF-1\/IGF-2 receptor","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Minghui Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Minghui Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"MHB018A","moa":"IGF-1\/IGF-2 receptor","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Minghui Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Minghui Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"MHB036C","moa":"Trop2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Minghui Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Minghui Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"MHB088C","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Minghui Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Minghui Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"MHB088C","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Minghui Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Minghui Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"MHB039A","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Minghui Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Minghui Pharmaceutical \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Minghui Pharmaceutical

    Menu

    Minghui Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Minghui Pharmaceutical

                            China arrow
                            German Wound Congress
                            Not Confirmed

                            Minghui Pharmaceutical

                            China arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tofacitinib Etocomil

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Minghui Announces Positive Results from Phase III Trial of MH004 in Atopic Dermatitis

                            Details : MH004 (tofacitinib etocomil) ointment 1.0%, a twice-daily pan-Jak inhibitor. It is being evaluated in late-stage clinical trial studies for the treating mild to moderate atopic dermatitis.

                            Product Name : MH004

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 29, 2024

                            Lead Product(s) : Tofacitinib Etocomil

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Minghui Pharmaceutical

                            China arrow
                            German Wound Congress
                            Not Confirmed

                            Minghui Pharmaceutical

                            China arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MHB018A

                            Therapeutic Area : Immunology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Minghui Reports Positive Results for IGF-1R Antibody in Thyroid Eye Disease

                            Details : MHB018A is a novel subcutaneous VHH-Fc fusion protein that targets the insulin-like growth factor-1 receptor (IGF-1R), a validated mechanism of action for Thyroid Eye Disease treatment.

                            Product Name : MHB018A

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            October 22, 2024

                            Lead Product(s) : MHB018A

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Minghui Pharmaceutical

                            China arrow
                            German Wound Congress
                            Not Confirmed

                            Minghui Pharmaceutical

                            China arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MHB088C

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Minghui Pharma to Present Phase I/II Results of MHB088C for Solid Tumors at ASCO Meeting

                            Details : MHB088C is a novel B7-H3 antibody-drug conjugate incorporating a potent DNA topoisomerase I inhibitor. It is being evaluated for the treatment of recurrent or metastatic solid tumors.

                            Product Name : MHB088C

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            August 05, 2024

                            Lead Product(s) : MHB088C

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Minghui Pharmaceutical

                            China arrow
                            German Wound Congress
                            Not Confirmed

                            Minghui Pharmaceutical

                            China arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MHB088C

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Minghui to Present Phase I/II Study of MHB088C for Metastatic Solid Tumors at ASCO 2024

                            Details : MHB088C is a novel B7-H3-targeting antibody-drug conjugate (ADC), which has demonstrated remarkable anti-tumor efficacy across various reccurent advanced cancer types.

                            Product Name : MHB088C

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            August 05, 2024

                            Lead Product(s) : MHB088C

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Minghui Pharmaceutical

                            China arrow
                            German Wound Congress
                            Not Confirmed

                            Minghui Pharmaceutical

                            China arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MHB039A

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Minghui Pharmaceutical Releases Phase I Data for MHB039A Bispecific Antibody in Tumors

                            Details : MHB039A, developed by Minghui Pharmaceutical, is a novel bispecific antibody targeting PD-1 and VEGF being developed in patients with relapsed/refractory solid tumors.

                            Product Name : MHB039A

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            June 11, 2024

                            Lead Product(s) : MHB039A

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Minghui Pharmaceutical

                            China arrow
                            German Wound Congress
                            Not Confirmed

                            Minghui Pharmaceutical

                            China arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tofacitinib Etocomil

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Minghui Pharmaceutical Inc. Announces First Patient Enrollment in the Phase 3 Clinical Study of MH004 Cream fo...

                            Details : MH004 is the investigational topical cream,currently in phase 3 clinical study for targeting mild to moderate atopic dermatitis. The topline data of the phase 3 trial with the medical community and regulatory authorities in H2 2024.

                            Product Name : MH004

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 17, 2023

                            Lead Product(s) : Tofacitinib Etocomil

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Minghui Pharmaceutical

                            China arrow
                            German Wound Congress
                            Not Confirmed

                            Minghui Pharmaceutical

                            China arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MHB036C

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Minghui Pharmaceutical Inc. Announces First Patient Dosing in Phase 1 Clinical Studies of Both the Antibody-Dr...

                            Details : MHB036C is an antibody drug conjugate composed of a humanized anti-TROP-2 monoclonal antibody conjugated to Minghui's proprietary DNA topoisomerase I inhibitor via a cleavable linker, investigated for metastatic solid tumors.

                            Product Name : MHB036C

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            June 20, 2023

                            Lead Product(s) : MHB036C

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Minghui Pharmaceutical

                            China arrow
                            German Wound Congress
                            Not Confirmed

                            Minghui Pharmaceutical

                            China arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MHB018A

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Minghui Pharmaceutical Inc. Announces First-in-Human Dose of MHB018A, a Subcutaneous Single-Domain IGF-1R Anti...

                            Details : MHB018A is a novel fusion protein of humanized single domain IGF-1R antibody and human Fc, which showed 3~5 times greater ligand blocking activities than other known IGF-1R antibodies for both IGF-1 and IGF-2.

                            Product Name : MHB018A

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            May 24, 2023

                            Lead Product(s) : MHB018A

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Minghui Pharmaceutical

                            China arrow
                            German Wound Congress
                            Not Confirmed

                            Minghui Pharmaceutical

                            China arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MHB018A

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Minghui Pharmaceutical Inc. Announces First-in-Human Dose of MHB018A, a Subcutaneous Single-Domain IGF-1R Anti...

                            Details : MHB018A is a novel fusion protein of humanized single domain IGF-1R antibody and human Fc, which showed 3~5 times greater ligand blocking activities than other known IGF-1R antibodies for both IGF-1 and IGF-2.

                            Product Name : MHB018A

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            May 23, 2023

                            Lead Product(s) : MHB018A

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Minghui Pharmaceutical

                            China arrow
                            German Wound Congress
                            Not Confirmed

                            Minghui Pharmaceutical

                            China arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tofacitinib Etocomil

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Minghui Pharmaceutical Inc. Announces Phase 2 Clinical Trial Success of MH004 Cream as a Potential Best-in-Cla...

                            Details : MH004 cream is a topical cream containing a JAK inhibitor, it is intended to be used for treatment of multiple dermatologic autoimmune diseases including atopic dermatitis.

                            Product Name : MH004

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 14, 2023

                            Lead Product(s) : Tofacitinib Etocomil

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth